

In-depth immune cellular profiling reveals sex-specific associations with frailty

Leonard Daniël Samson (✉ leon.samson@rivm.nl)

National Institute for Public Health and the Environment <https://orcid.org/0000-0002-6252-7639>

A. Mieke H. Boots

Universitair Medisch Centrum Groningen

José A. Ferreira

Rijksinstituut voor Volksgezondheid en Milieu

H. Susan J. Picavet

Rijksinstituut voor Volksgezondheid en Milieu

Lia G. H. De Rond

Rijksinstituut voor Volksgezondheid en Milieu

Mary-lène de Zeeuw-Brouwer

Rijksinstituut voor Volksgezondheid en Milieu

W. M. Monique Verschuren

Rijksinstituut voor Volksgezondheid en Milieu

Anne-Marie Buisman

Rijksinstituut voor Volksgezondheid en Milieu

Peter Engelfriet

Rijksinstituut voor Volksgezondheid en Milieu

Research

Keywords: frailty, immune cellular profiling, immunosenescence, immune homeostasis, healthy aging

Posted Date: March 10th, 2020

DOI: <https://doi.org/10.21203/rs.2.19660/v2>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published on June 23rd, 2020. See the published version at <https://doi.org/10.1186/s12979-020-00191-z>.

RESEARCH

In-depth immune cellular profiling reveals sex-specific associations with frailty

Leonard Daniël Samson^{1,2*}, A. Mieke H. Boots², José A. Ferreira¹, H. Susan J. Picavet¹, Lia G. H. de Rond¹, Mary-lène de Zeeuw-Brouwer¹, W. M. Monique Verschuren^{1,3}, Anne-Marie Buisman¹ and Peter Engelfriet¹

*Correspondence:
leon.samson@rivm.nl

¹National Institute of Public Health and the Environment, Bilthoven, The Netherlands,

Full list of author information is available at the end of the article

Abstract

Background: With advancing age, the composition of leukocyte subpopulations in peripheral blood is known to change, but how this change differs between men and women and how it relates to frailty is poorly understood. Thus, our aim in this exploratory study was to investigate whether frailty is associated with changes in immune cell subpopulations and whether associations differ between men and women. Therefore, we performed in-depth immune cell phenotyping by enumerating a total of 37 subsets of T cells, B cells, NK cells, monocytes, and neutrophils in peripheral blood of 289 elderly people between 60-87 years of age. Associations between frailty and each immune cell subpopulation were tested separately in men and women and were adjusted for age and CMV serostatus. In addition, a random forest algorithm was used to predict a participant's frailty score based on enumeration of immune cell subpopulations.

Results: In an association study, frailty was observed to be associated with increases in numbers of neutrophils in both men and in women. Furthermore, sex-specific associations were found. Frailer women, but not men, showed higher numbers of total and CD16⁻ monocytes and lower numbers of CD56⁺ T cells. Overall, the accuracy of the predictions in the random forest analysis was low (9.2% explained variance in men and 12.2% in women). Yet, the random forest analysis confirmed all associations mentioned above, but did not confirm a possible negative association between frailty and late differentiated CD4⁺ TemRA cells in women. Moreover, the random forest analysis revealed additional relationships with frailty, with frailer men showing higher CD16⁺ monocytes and lower naïve B cell numbers. Other important variables for predicting frailty were plasmablast numbers in men and total T cell numbers in women.

Conclusions: We report on observed associations of frailty with elevated myeloid cell numbers in men and women. In-depth immune cellular profiling also revealed sex-specific associations of frailty with several immune subpopulations. However, an expected positive association between frailty and memory T cells was not observed. We hope that our study will prompt further investigation into the immune mechanisms associated with the development of frailty in men and women.

Keywords: frailty; immune cellular profiling; immunosenescence; immune homeostasis; healthy aging

1 Background

While aging is inevitable, some people remain healthy until an advanced age while others suffer from age-related diseases early in life. The reasons for these vastly different aging patterns are still poorly understood. To protect the body from damage normally associated with aging, a balanced immune system is needed [1], with different subsets of immune cells working in close harmony. One telling sign of a disturbed immune balance is a state of chronic low-grade inflammation, which may be revealed by measuring biomarkers such as C-reactive protein [1, 2, 3]. It remains a challenge, however, to identify other biomarkers of the immune system that signal or explain differences in aging patterns.

Both innate and adaptive immune cell lineages are essential for a proper functioning of the immune system. It is well-established that the composition of the immune cell repertoire—that is the relative and absolute abundances of the various subsets of immune cells—changes with age [4]. However, it is largely unknown how changes in the immune cellular composition differ in individuals who age in good health from those who become frail at a relatively early age. Several studies have been performed on this subject, but some of these were done in the extreme elderly of 85 years old or above [5], while others focused on a limited set of lymphocyte phenotypes [6, 7, 8]. Importantly, few studies have been performed enumerating a comprehensive set of immune phenotypes in freshly drawn whole blood samples.

Recently, we investigated associations between frailty and absolute numbers of the major immune cell subsets in fresh whole blood. In that study, we detected associations between frailty and numbers of granulocytes and monocytes [3]. However, given the complex nature of the immune system and its specialized functions, that are mediated by various immune cell subpopulations, it is to be expected that changes in major immune cell subsets are accompanied by more subtle, yet potentially important, shifts in smaller subpopulations that are functionally distinct. This hypothesis prompted us to extend our previous study with an in-depth analysis of frailty in relation to various immune cell subpopulations.

Since men and women tend to age differently [9], we deemed it important to consider differences between the sexes. Furthermore, cytomegalovirus (CMV) serostatus should be taken into account, because chronic CMV infection is well known to impact numbers of immune cell subpopulations [10, 11]. The exploratory approach taken in this study involves the investigation of a large number of potential relations between variables. Moreover, given the heterogeneity of our study population, these variables are expected to show much variability. Due care should thus be taken in choosing appropriate methods of analysis that keep the risk of finding spurious associations within bounds, while at the same time allowing the detection of real associations. Therefore, we analyzed the data using robust, “non-parametric”, methods of analysis, as further described below.

Thus, our main goal in this study was to explore how general health, as expressed in terms of a frailty index, is associated with an extensive set of immune cell subpopulations in peripheral blood of older adults. Our secondary goal was to explore how these immune cell subpopulations differ between the sexes or according

to CMV serostatus. In order to do so, we employed extensive immune profiling, enumerating 37 immune subsets and describing the expression of several surface markers on immune cells in fresh whole blood samples from 289 older people aged between 60-87 years that were selected from participants in an ongoing cohort study in the Netherlands [12, 13].

2 Methods

2.1 DCS subcohort selection

A subcohort was selected from the Doetinchem cohort study (DCS) [12, 13]. Details on this subcohort and its selection have been described previously [3]. Briefly, the study involved 289 active DCS participants, aged 60-87 years, who were selected as an age- and sex- stratified sample, with selection of equal numbers of the healthiest, intermediate, and frailest participants. By healthiest/frailest we mean those belonging to the 15% individuals with the lowest/highest frailty index score (see below for the definition of frailty index) compared to their age- and sex-matched peers. By intermediate we mean the remaining 70% of the DCS participants.

2.2 Frailty index

A frailty index was constructed based on previous studies [5, 14, 15, 16] and was adapted to the data available in the DCS; it was recently validated within the DCS by [3]. This frailty index incorporates 36 possible “health deficits” such as presence of chronic disease or reduced physical functioning. The values of the frailty index are restricted to lie between zero and one, zero representing the ‘best’ (0 out of 36 deficits present) and one representing the ‘worst’ (all 36 deficits present) health status. Since it has 36 categories, this frailty index is by approximation a continuous variable. Using the index, a frailty ‘score’ was calculated for each individual, based on data collected during the DCS assessment round 6 (2012-2017). Twelve out of 289 individuals who had participated in our DCS subcohort, had not participated in DCS assessment round 6 and thus, their frailty index score was missing.

2.3 Whole blood lymphocyte phenotyping

Fresh whole blood samples from the DCS subcohort participants were collected between August 2016 and March 2017 and were processed and analyzed within 6 hours on a 4-laser LSRII Fortessa X20 flow cytometer (BD Biosciences) for absolute numbers of leukocyte subsets (cell counts μL^{-1}). Two labeled antibody panels per participant were used with a lyse-no-wash protocol, one in a TruCOUNT[®] tube (BD Biosciences) and one in a common Falcon tube. In both panels we used the fluorochrome-conjugated antibodies CD3(UCHT1)-BV711 (BD) and CD27(M-T271)-BV421 (Biolegend). In the TruCOUNT[®] tube, we additionally used CD56(B159)-APC, CD8(SK1)-FITC, CD16(B73.1)-PE, CD4(SK3)-PerCPCy5.5, IgD(ia6-2)-BB515, CD38(HB7)-APC-H7, HLA-DR(G46.6)-PECF594 (all BD Biosciences), CD19(J3-119)-PECy7 (Beckman Coulter), and CD45(GA90)-OC515 (Cytognos). In the second tube we additionally used the following fluorochrome-conjugated antibodies: CD127(hIL-7R-M21)-PE, CD25(2A3)-BB515, CCR7(150503)-PECF594, CD28(CD28.2)-PerCPCy5.5, CD8(SK1)-APC-H7 (all BD Biosciences), CD4(RPA-T4)-BV510, CD45RA(HI100)-BV650 (all Biolegend), and CXCR5(51505)-APC (R&D Systems). Absolute cell numbers in the Falcon tube were calculated

by using the CD3 T cell ratio between both tubes and the bead count in the TruCOUNT[®] tube.

For phenotype definitions and gating strategies, see Table S1 and Figures S1, S2, and S3. Neutrophils were gated as CD45 and SSC^{BRIGHT} and CD45^{DIM} and were additionally analyzed not only regarding cell numbers but also with respect to CD16 expression. CD16 is usually expressed on the surface of neutrophils [17] and is seen as a neutrophil maturation marker [18]. Lower expression of CD16 by neutrophils was seen in several diseases and in states of neutropenia [19]. Monocytes were gated as SSC^{DIM}CD45^{DIM} and, to ensure that B cells or T cells did not contaminate the gate, as CD3⁻CD19⁻. Monocytes were further sub-classified into non-classical and classical monocytes based on CD16 expression, and were additionally analyzed based on the expression of HLA-DR and CD38, since HLA-DR expression on monocytes is thought to be lower [20] and CD38 expression higher [21] in inflammatory conditions. NK cells were gated and subdivided based on their CD16 and CD56 expression [22]. For memory T cells and regulatory T cells, gating was done as described previously [23, 24, 25] and was performed similarly in both CD4⁺ and CD8⁺ T cells. In short, CCR7⁺ CD4⁺/CD8⁺ T cells were classified as either naïve (CD45RA⁺CCR7⁺) or central memory (CCR7⁺CD45RA⁻) T cells. CCR7⁻ CD4⁺/CD8⁺ T cells were divided into effector memory T cells (Tem, CCR7⁻CD45RA⁻) and effector memory T cells re-expressing CD45RA (TemRA, CCR7⁻CD45RA⁺) T cells. Finally, these T cells were further subclassified into early (CD27⁺CD28⁺) and late stage (CD27⁻CD28⁻) Tem or TemRA cells. The B cell subsets were defined by means of CD19, CD27, and CD38 expression [24], with naïve B cells defined as CD19⁺CD38^{DIM}CD27⁻ and memory B cells as CD19⁺CD38^{DIM}CD27⁺ (Figure S3 and Table S1). As an additional analysis, we also calculated proportions of the immune cell subpopulations. Proportions were expressed as the percentage of their major cell lineage (T cells, B cells, NK cells, or monocytes) or, for all CD4⁺ and CD8⁺ subpopulations, as the percentage of CD4⁺ and CD8⁺ T cells, respectively. Some subpopulations were not clearly distinguishable from debris and the corresponding data were excluded from analysis. This occurred for the general lymphocyte subset in four participants, for the monocyte subsets in three participants, and for both the lymphocyte and monocyte subsets in three participants. Unwanted fluorochrome excitation spillover was automatically corrected for by using BDComp beads (BD Biosciences). Gating of cellular subsets was performed in FlowJo V10 (FlowJo company).

2.4 Anti-cytomegalovirus antibodies

IgG antibodies against CMV were quantified using a multiplex immunoassay (MIA) that was developed in-house and was based on a commercially available Cytomegalovirus IgG ELISA kit (EUROIMMUN, Germany) [26]. A cutoff for CMV-seropositivity was calculated by first pooling IgG CMV antibody concentrations of people from multiple cohorts [27, 3, 28, 29], with all concentrations measured using the same in-house developed assay (n=1415, age range: 4-89 years). With these pooled concentrations, we used mixture modeling [30] to define two distributions, representing respectively CMV-seronegative and CMV-seropositive individuals. The CMV-seropositivity cutoff was defined as the intersection between the two distributions, as described previously for varicella zoster virus [31].

2.5 Statistical methods

As this was an exploratory study investigating a large number of variables and their mutual relations, and moreover, a considerable variability in the measured quantities was expected between individuals, ‘robust’ statistical methods were chosen. By ‘robust’ we mean that the number of assumptions needed to be met to obtain valid results is kept to a minimum, and therefore the results remain reliable under a wide variety of conditions. For example, unlike more commonly used techniques of analysis, such as linear regression, analyses are still valid when variables are non-normally distributed, or when they are related in a non-linear manner, or when there is strong multicollinearity. In addition, due care was taken to adjust for multiple testing. In particular, all the findings mentioned below have gone through the Benjamini Hochberg method [32] that was applied separately to each association study at a False Discovery Rate (FDR) of 15%. This means that, roughly speaking, of all the findings here reported at most 15% could be spurious.

We first focused on our secondary objective, which was to study how immune cell subpopulations differ between the sexes and between CMV seropositive and seronegative individuals, while taking age into account. Therefore, we carried out an association study to detect associations between sex and each of the subsets of immune cells, and between CMV serostatus and each of the subsets of immune cells. Differences according to sex and CMV serostatus with respect to each leukocyte phenotype were tested with the permutation version of the Wilcoxon-Mann-Whitney test [33], blocked by age in four age groups to reduce possible confounding effects of age. For the comparison between sexes, the age groups were further subdivided according to CMV serostatus. Since we used a permutation approach, P values were calculated using 10^8 simulations to estimate the distribution under the null hypothesis. In addition, a Spearman’s rho was calculated separately, and defined as the weighted average of Spearman’s rho within each block. This was done as Spearman’s rho, not used in calculating p values (which was done by simulations), is useful for estimating the strength of an association. This type of analysis has the advantage over more commonly used tests that no pre-defined assumptions need to be made concerning, for example, the distribution of the data. In addition, ties in ranking, that can occur when ranking variables, such as a frailty index score, do not pose a concern when calculating p values using a permutation approach [34].

Secondly, we focused on our main objective, which was to study how frailty relates to numbers of immune cell subsets and how this relationship differs between the sexes, while taking age and CMV serostatus into account. For this purpose, two complementary analyses were carried out: (A) separate association studies for men and women to detect associations between frailty and each of the cell subsets, and (B) separate analyses for men and women in which a participant’s frailty index was predicted based on age, CMV serostatus and date of flow cytometry measurement, in combination with the participant’s immune cell numbers. For (A), associations between frailty and each subset of immune cells were assessed with the permutation version of the Spearman correlation test [33] blocked by eight strata based on four age categories and CMV serostatus. P-values were estimated and Spearman’s rho calculated in a similar manner as with the association studies described above. For (B), a random forest predictor was used [35] chiefly with the purpose of obtaining

a ranking of variable importance and to complement the association studies by considering several variables simultaneously. Roughly speaking, in a random forest the importance of a variable is measured in terms of the percentage increase in mean-square error (MSE) that results from randomly shuffling the values of that variable in the data set, so that greater importance is synonymous with greater increase in MSE; see [35] for details. Furthermore, the prediction analysis was assessed in terms of the explained variance. Then, in order to provide a qualitative idea of the relationships between the most important predictor variables and the frailty index, partial dependence plots were created with the *pdp* R package [36]. This random forest algorithm is known for its accuracy in complex analyses [37, 38, 39]. Therefore, it has been used in a wide variety of research disciplines when many explanatory variables are involved [40, 41, 42, 39]. The algorithm is robust and reliable since, unlike more traditional methods like linear regression models, it can handle multiple explanatory variables that do not need to be normally distributed [37] such as the cell subpopulations in this study. Other advantages of the random forest algorithm when compared to more traditional methods are that it even performs well if strong multicollinearity exists between explanatory variables and that the model does not tend to overfit when using multiple explanatory variables [37, 35].

3 Results

3.1 Study population

The study population consisted of 145 men and 144 women. Average time between blood sample collection and frailty index measurement was 1.6 years (95%CI: 1.4-1.8 years, min: 2 days, max: 4.25 years). Since $n=5$ men and $n=7$ women did not participate in the latest DCS assessment round and therefore had a missing frailty index score, these participants were removed from the analyses with frailty.

3.2 Associations between leukocyte subpopulations and sex

An overview of immune cell phenotypes considered in this study is given in Figure 1, all of them measured in peripheral blood. Most of the analyzed subpopulations belong to the T cell lineage. Neutrophils accounted for the highest median numbers in peripheral blood of both men and women, followed by T cells (Figure 2). Women had lower numbers of CD16⁻ (classical) monocytes but higher numbers of B cells and T cells than men. The higher numbers of T cells in women were mainly due to higher CD4⁺ T cell numbers. Further subsetting revealed higher concentrations of almost all CD4 T cell subpopulations (naïve CD4 T cells, central memory CD4 T cells, CD4 Tem and TemRA cells, (naïve) regulatory T cells, and Follicular helper T cells) in peripheral blood of women. This pattern was also seen in early differentiated CD4 subsets but, in contrast, not in late differentiated CD4 Tem cells which showed lower numbers in women (Figure 3). Furthermore, we also observed lower numbers of CD56⁺ T cells in women. While total numbers of CD8⁺ T cells were not found to be different between the sexes, CD8 naïve T cell numbers were found to be higher in women (Figure 2). More detailed phenotyping of CD8 T cell subpopulations revealed higher numbers of early differentiated CD8 Tem and TemRA cells in women than in men, but lower numbers of late differentiated CD8 Tem and TemRA cells (Figure 3).

3.3 Associations between leukocyte subpopulations and CMV serostatus

CMV seropositivity was associated with higher numbers of T cells and CD56⁺ T cells in men and in women (Table S2). Numbers of CD8⁺ T cells were observed to be higher in CMV seropositive (CMV⁺) men and CMV⁺ women, which was mainly due to higher numbers of late stage CD8⁺ Tem and TemRA cells. Numbers of CD4⁺ T cells were observed to be higher in CMV⁺ men but not in CMV⁺ women. However, late stage CD4⁺ Tem and TemRA cells were higher in CMV⁺ men and CMV⁺ women. Also, the CD4/CD8 ratio was lower in CMV seropositive individuals of both sexes, indicating that the higher T cell numbers in CMV⁺ participants was more due to the higher numbers of CD8⁺ T cells rather than CD4⁺ T cells. In men, CMV seropositivity was also associated with higher numbers of follicular helper T cells and with lower numbers of monocytes due to lower numbers of CD16⁻ (classical) monocytes. These classical monocytes also showed higher CD38 expression.

3.4 Relationship of frailty with leukocyte subpopulations

In the association study, an association between frailty and higher neutrophil numbers was found in men and in women (tables S3 and S4), while other associations were observed only in women. Frailer women, but not men, showed higher monocyte numbers, in particular classical monocyte numbers. In addition, frailer women also showed lower CD56⁺ T cell numbers and lower CD4⁺ TemRA cell numbers. Interestingly, frailty was not found to be associated with any other T cell subpopulation and thus, not with most memory T cell subpopulations.

In the prediction analysis with the random forest algorithm, predictive power turned out to be weak in both of the sexes with the percentage of explained variance being 9.2% in men and 12.2% in women. Variable importance of the subpopulations showed that neutrophils were the only subpopulations among the most important variables in the model to predict frailty in men and in women (Figure 4, with 'most important' variables, defined as >50% increase in MSE, shown in bold). Other relationships between frailty and the immune cell profile were sex-specific. The subpopulations with highest increase in MSE were neutrophils in women and CD16⁺ monocytes in men. In women, other monocyte subpopulations were found among the most important subpopulations related to frailty, namely total monocytes and CD16⁻ monocytes. Furthermore, among the most important subpopulations related to frailty in men were also naïve B cells and plasmablasts, and in women CD56⁺ T cells and total T cells. Age was also an important variable to predict frailty in both sexes. Interestingly, CMV serostatus was not important in the prediction model, with an increase in MSE of less than 0.5% in either of the sexes.

An overall impression of the strength and quality of the role of the more important variables in predicting frailty is provided by the partial dependence plots shown in Figure 5. These show the 'effect' of a cell type on frailty when the other variables in the random forest predictor are held constant at average values. The clearer and stronger relationships with frailty were seen in the myeloid cell numbers. In accordance with the association study, an increase in neutrophil numbers was seen with a higher frailty index in both men and women. An increase in numbers of classical monocytes with frailty was only seen in women, and an increase in non-classical monocytes with frailty was only seen in men. Moreover, frailer men but not

women demonstrated lower naïve B cell numbers and frailer women showed lower CD56⁺ T cells. The direction of the relationship between frailty and plasmablast numbers in men was less clear, with the partial dependence plot showing a possible non-monotonous ‘U-shaped’ relationship.

3.5 Associations between frailty and proportions of leukocyte subpopulations

We additionally investigated whether frailty was associated with relative values (percentages) of immune cell subpopulations within the major parent populations (that is, within T cells, B cells, monocytes, and NK cells). In this analysis, no associations with frailty were detected (Tables S5 and S6).

4 Discussion

This study shows that frailty in a 60-87-year-old population was associated with higher absolute numbers of neutrophils in men and women, and also with several sex-specific changes in the immune cellular profile. Frailer women demonstrated higher numbers of total monocytes and CD16⁻ monocytes and lower numbers of CD56⁺ T cells in both an association study and in a prediction analysis. We also observed a negative association between frailty and late differentiated CD4⁺ TemRA cells, but this result was not confirmed in the prediction analysis. Overall, the predictive value of the random forest model was low. Yet, the random forest model revealed additional sex-specific relationships with frailty, showing that higher frailty index scores were related to higher CD16⁺ monocyte and lower naïve B cell numbers in men. Notably, we detected no positive associations between frailty and memory T cell subpopulations.

To the best of our knowledge, this is the first study in which frailty was investigated for associations with different monocyte subpopulations. The most abundant monocytes are the classical CD16⁻ monocytes. These have clear phagocytic capacity, can evolve into macrophages [43] and therefore are involved in defense against pathogens. Classical monocytes can also evolve into a rarer subpopulation, the non-classical monocytes [44]. Our CD16⁺ monocyte subpopulation consists of both non-classical and intermediate monocytes, of which non-classical monocytes are thought to be the most matured subset [44]. Evidence is conflicting about whether non-classical monocytes have a pro-inflammatory [43, 45] or a more regulatory role [46]. However, they seem to be involved in vascular homeostasis and atherosclerosis by patrolling vascular endothelia [47], and their numbers are elevated in numerous other diseases and conditions like sepsis [43], arthritis [48], and atherosclerosis [47]. This indicates that they play an important role in mediating health and disease. In addition, non-classical monocytes seem to be involved in vascular homeostasis by patrolling vascular endothelia and controlling plaque formation in atherosclerosis [47]. The fact that conditions like atherosclerosis are more common in men, possibly due to a ‘protective’ effect of estrogen in women [49], might help to explain why we observed higher numbers of non-classical monocytes in frailer men. We also observed lower numbers of T cells expressing the NK cell marker CD56 in frailer women, but not men. The relationship of frailty with CD56⁺ T cells has not been described earlier. However, in one study NK cell markers (CD16 and CD56) were shown to be more highly expressed by T cells from people with better cognitive and physical

functioning [50], a finding that corresponds to the negative relationship found in our study between $CD56^+$ T cell numbers and frailty in women. Furthermore, in the prediction analysis we observed other relationships between frailty and the immune cellular profile, such as lower naïve ($CD19^+CD38^{DIM}CD27^-$) B cell numbers in frailer men, and a non-monotonous relationship between frailty and plasmablasts in men, but not women. Sex-specific associations between frailty and B cell subpopulations were described in a recently published paper, in which the authors observed that men with a higher frailty index score had higher double negative ($CD27^-$ and IgD^-) memory B cell percentages [51]. Although we did not use IgD to distinguish the $CD27^-IgD^-$ memory B cell subset from the naïve $CD27^-$ B cell population, it could be that a higher proportion of double negative memory B cells, as observed by Nevalainen *et al.*, is explained by lower absolute numbers of $CD27^+IgD^+$ naïve B cells, which would be in line with our findings, a notion to be further investigated. Thus, frailer men showed higher non-classical monocyte numbers and possibly lower naïve B cell numbers, while frailer women showed higher classical monocytes and lower $CD56^+$ T cells. These findings could be of interest in relation to the sex-frailty paradox, namely that women on average are frailer than men but tend to live longer [52]. Further insight may eventually lead to a better understanding of the mechanisms underlying this paradox.

The associations found between higher myeloid cell numbers and frailty are in line with previous reports [5, 53, 3]. In one study it was shown that elevated neutrophil levels in humans are related to negative health outcomes [54], which corresponds to our results, since frail people are more prone to adverse outcomes like early mortality. In a murine study, it was argued that both higher myeloid cell abundancies and lower vaccine responses in older mice could be the result of intrinsic differences in hematopoietic stem cells [55]. Other studies suggest that the myeloid bias of hematopoietic stem cell differentiation seen in old age is due to a chronic low-grade inflammation [56]. This process is possibly regulated by plasma cells in bone marrow that can produce pro-inflammatory cytokines that are shown to be related to myelopoiesis [57]. Such a chronic low-grade inflammation is often seen in frail people [58]. However, many other factors may impact cellular numbers in peripheral blood, like variations in extravascular homing, or differential apoptosis [59].

Interestingly, in this study no positive associations were found between frailty and naïve- and memory T cell subpopulations in either of the sexes. This is of interest because it is known that the balance between naïve and memory T cells in peripheral blood changes with advancing age, mainly due to lower numbers of naïve ($CD8^+$) T cells [60, 61, 11], which was also observed in our study (data not shown). However, instead of a positive association, we observed a negative association between late differentiated $CD4^+$ TemRA cells and frailty in women. But since it was the weakest observed association in women and the association was not confirmed in the random forest analysis, the importance of this result requires confirmation in future studies. Previous studies, analyzing fewer immune cell subpopulations, did not detect associations between frailty and naïve- and memory T cell subpopulations [5, 7]. However, contrasting results were found in the Singapore Longitudinal Aging Study population, in which associations were found between frailty and memory

T cell subpopulations, as well as with CD4/CD8 ratio [6, 62]. But the results of these studies were based on the analysis of a relatively small frail population (32 participants) without adjustments for cytomegalovirus (CMV) infection, which is well known to generate clonal expansion of memory T cells and thus may have confounded this study. In our study we confirmed previously found associations of CMV seropositivity with the late-stage memory T cell population [25, 11]. We also observed that CMV seropositive men had lower classical monocyte numbers. In addition, their classical monocytes seemed to have higher CD38 expression. It is thought that CD38 can be upregulated in monocytes and macrophages in inflammatory conditions [21]. Further research is needed to confirm this association and to answer the question why it was only found in men. Furthermore, we observed that CMV serostatus was not important in our frailty prediction model. Conflicting evidence has been reported on whether there is a positive relationship between CMV serostatus and frailty, with some studies showing an association [63, 64] while others do not [5, 65]. These conflicting results might be explained by differences in the frailty instruments used (Frailty phenotype or frailty index) or differences in study population, with some studies being restricted to only one of the sexes [63] or to extreme elderly [5, 65].

The present study also shows that several immune cell subpopulations differ in abundance between the sexes, with higher numbers of most T cell subpopulations, especially CD4 T helper cells, and higher numbers of B cells in women. These findings are in line with previous studies [25]. Immunological homeostasis in women may involve a different balance between CD4 and CD8 T cells than in men, with estrogen levels known to be involved in lymphocyte development and in particular CD4 T cell proliferation [66, 67]. In addition, immune function differs between the sexes, with women showing better responses to antigens and a stronger tendency to develop autoimmune diseases [52, 66].

One of the strengths of this study is the use of fresh whole blood samples to measure an extensive set of immune cell subpopulations. This made it possible to enumerate cell populations like neutrophils that are not possible to quantify when using cryopreserved PBMCs. In addition, we were able to relate absolute numbers of 37 immune subsets to frailty. This is important as these are needed to correctly interpret relative values (e.g. percentages). As an example, a change in relative values can be the result of a change in either the numerator or the denominator. This issue can be solved only with information on absolute numbers. Our study also showed that, when we performed an analysis with subpopulations of B cells, T cells, NK cells, and monocytes expressed as percentages, this analysis did not give additional insight in how frailty relates to the immune cellular profile. Another strength of our study is that we used a robust statistical analysis framework with two different analytical approaches that complement each other to find associations with frailty while correcting for multiple testing. In our statistical analysis framework, we also adjusted for age and CMV serostatus in the association study between frailty and the immune cellular profile by using four age groups and CMV serostatus as blocking factors. Moreover, another noteworthy asset of our study is that it concerned a sample from the general community-dwelling population, thus allowing a window

on aging of the immune system in a non-clinical setting. On the other hand, due to the nature of using fresh whole blood samples and our aim being to quantify a large number of different immune cell subpopulations, we were restricted in our antibody panel and therefore not all the subsets could be further classified with additional phenotypic markers. For example, to define regulatory T cells we used CD45RA and CD25 as was done previously [23, 24, 25], but not FoxP3 or CD127. In addition, it appeared, as already expected, that the variability in numbers of immune cell subsets is very large in older adults. This may have contributed to the low prediction accuracy observed in the prediction analysis. Furthermore, there is no consensus yet on which instrument is the best to investigate frailty, and different instruments might yield different results. Since we were interested in a measure that approximates general health, we used a Rockwood frailty index [16] based on 36 deficits rather than a frailty instrument with a less broad definition like the Fried frailty phenotype [68].

5 Conclusions

In this study we found associations between frailty and higher neutrophil numbers in both men and women, but not between frailty and higher memory T cell numbers. In-depth immune profiling also revealed sex-specific associations with frailty, with frailer women but not men showing higher numbers of classical monocytes and lower numbers of CD56⁺ T cells than their healthier peers.. These sex-specific associations, to the best of our knowledge, have not been reported earlier. An expected positive association between frailty and memory T cells was not observed. We hope that our study will prompt further investigation into the different immune mechanisms associated with the development of frailty in men and women.

Abbreviations

CMV: Cytomegalovirus; DCS: Doetinchem Cohort Study; FDR: False Discovery Rate; Tem: effector memory T cells; TemRA: effector memory T cells re-expressing CD45RA

Acknowledgements

We would like to thank the DCS respondents for their participation in the study and the epidemiologists and fieldworkers of the Municipal Health Service in Doetinchem for their contribution to the data collection. In addition, we would like to thank Petra Vissink for her help with the blood sample collection, and Sara van den Berg, Marjan Bogaard, and Irina Tcherniaeva for their help with the cytomegalovirus assay.

Authors' contributions

SP and MV contributed to the development and maintenance of the Doetinchem Cohort Study. LS, PE, AB, and MB developed and implemented the DCS subcohort study design. MZ, LdR, and LS developed the flow cytometry laboratory protocols and performed the experimental work in the laboratory. JF provided the concept of the data analysis framework, and LS, JF, and PE implemented it in the manuscript. LS, PE, JF, AB, MB, and MV interpreted the data and drafted the manuscript. All authors read and approved the final manuscript.

Funding

The Doetinchem Cohort Study is funded by the Dutch Ministry of Health, Welfare and Sport. Additional funding for the current study was also provided by the Ministry. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials

The datasets used are available from the corresponding author upon reasonable request and with permission of the scientific committee of the Doetinchem Cohort Study.

Ethical approval and consent to participate

The study was approved by the Medical Ethics Committee of the University Medical Center in Utrecht, The Netherlands. The participants gave written informed consent for every DCS round and for this subcohort study separately.

Consent for publication

Not applicable

Competing Interest

The authors declare that they have no competing interests

Author details

¹National Institute of Public Health and the Environment, Bilthoven, The Netherlands., ²Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, The Netherlands. ³Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

References

- Campisi, J., Kapahi, P., Lithgow, G.J., Melov, S., Newman, J.C., Verdin, E.: From discoveries in ageing research to therapeutics for healthy ageing. *Nature* **571**(7764), 183–192 (2019). doi:[10.1038/s41586-019-1365-2](https://doi.org/10.1038/s41586-019-1365-2)
- Franceschi, C., Campisi, J.: Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. *J Gerontol A Biol Sci Med Sci* **69 Suppl 1**, 4–9 (2014). doi:[10.1093/gerona/glu057](https://doi.org/10.1093/gerona/glu057)
- Samson, L.D., Boots, A.M.H., Verschuren, W.M.M., Picavet, H.S.J., Engelfriet, P., Buisman, A.-M.: Frailty is associated with elevated CRP trajectories and higher numbers of neutrophils and monocytes. *Experimental Gerontology* **125**, 110674 (2019). doi:[10.1016/j.exger.2019.110674](https://doi.org/10.1016/j.exger.2019.110674)
- Carr, E.J., Dooley, J., Garcia-Perez, J.E., Lagou, V., Lee, J.C., Wouters, C., Meyts, I., Goris, A., Boeckstaens, G., Linterman, M.A., Liston, A.: The cellular composition of the human immune system is shaped by age and cohabitation. *Nat Immunol* **17**(4), 461–8 (2016). doi:[10.1038/ni.3371](https://doi.org/10.1038/ni.3371)
- Collerton, J., Martin-Ruiz, C., Davies, K., Hilkens, C.M., Isaacs, J., Kolenda, C., Parker, C., Dunn, M., Catt, M., Jagger, C., von Zglinicki, T., Kirkwood, T.B.: Frailty and the role of inflammation, immunosenescence and cellular ageing in the very old: Cross-sectional findings from the Newcastle 85+ Study. *Mech Ageing Dev* **133**(6), 456–66 (2012). doi:[10.1016/j.mad.2012.05.005](https://doi.org/10.1016/j.mad.2012.05.005)
- Lu, Y., Tan, C.T.Y., Nyunt, M.S.Z., Mok, E.W.H., Camous, X., Kared, H., Fulop, T., Feng, L., Ng, T.P., Larbi, A.: Inflammatory and immune markers associated with physical frailty syndrome: Findings from Singapore longitudinal aging studies. *Oncotarget* **7**(20) (2016). doi:[10.18632/oncotarget.8939](https://doi.org/10.18632/oncotarget.8939)
- Marcos-Pérez, D., Sánchez-Flores, M., Maseda, A., Lorenzo-López, L., Millán-Calenti, J.C., Gostner, J.M., Fuchs, D., Pásaro, E., Laffon, B., Valdíglesias, V.: Frailty in Older Adults Is Associated With Plasma Concentrations of Inflammatory Mediators but Not With Lymphocyte Subpopulations. *Frontiers in Immunology* **9**, 1056 (2018). doi:[10.3389/fimmu.2018.01056](https://doi.org/10.3389/fimmu.2018.01056)
- Johnstone, J., Parsons, R., Botelho, F., Millar, J., McNeil, S., Fulop, T., McElhaney, J.E., Andrew, M.K., Walter, S.D., Devereaux, P.J., Malek, M., Brinkman, R.R., Bramson, J., Loeb, M.: T-Cell Phenotypes Predictive of Frailty and Mortality in Elderly Nursing Home Residents. *Journal of the American Geriatrics Society*, (2016). doi:[10.1111/jgs.14507](https://doi.org/10.1111/jgs.14507)
- Gordon, E.H., Peel, N.M., Samanta, M., Theou, O., Howlett, S.E., Hubbard, R.E.: Sex differences in frailty: A systematic review and meta-analysis. *Experimental Gerontology* **89**, 30–40 (2017). doi:[10.1016/j.exger.2016.12.021](https://doi.org/10.1016/j.exger.2016.12.021)
- Apoil, P.A., Puissant-Lubrano, B., Congy-Jolivet, N., Peres, M., Tkaczuk, J., Roubinet, F., Blancher, A.: Influence of age, sex and HCMV-serostatus on blood lymphocyte subpopulations in healthy adults. *Cell Immunol* **314**, 42–53 (2017). doi:[10.1016/j.cellimm.2017.02.001](https://doi.org/10.1016/j.cellimm.2017.02.001)
- Wertheimer, A.M., Bennett, M.S., Park, B., Uhrlaub, J.L., Martinez, C., Pulko, V., Currier, N.L., Nikolich-Zugich, D., Kaye, J., Nikolich-Zugich, J.: Aging and cytomegalovirus infection differentially and jointly affect distinct circulating T cell subsets in humans. *J Immunol* **192**(5), 2143–55 (2014). doi:[10.4049/jimmunol.1301721](https://doi.org/10.4049/jimmunol.1301721)
- Picavet, H.S.J., Blokstra, A., Spijkerman, A.M.W., Verschuren, W.M.M.: Cohort Profile Update: The Doetinchem Cohort Study 1987-2017: Lifestyle, health and chronic diseases in a life course and ageing perspective. *Int J Epidemiol* **46**(6), 1751–1751 (2017). doi:[10.1093/ije/dyx103](https://doi.org/10.1093/ije/dyx103)
- Verschuren, W.M., Blokstra, A., Picavet, H.S., Smit, H.A.: Cohort profile: The Doetinchem Cohort Study. *Int J Epidemiol* **37**(6), 1236–41 (2008). doi:[10.1093/ije/dym292](https://doi.org/10.1093/ije/dym292)
- Rockwood, K., Song, X., Mitnitski, A.: Changes in relative fitness and frailty across the adult lifespan: Evidence from the Canadian National Population Health Survey. *Canadian Medical Association Journal* **183**(8), 487–494 (2011). doi:[10.1503/cmaj.101271](https://doi.org/10.1503/cmaj.101271)
- Schoufour, J.D., Erler, N.S., Jaspers, L., Kiefte-de Jong, J.C., Voortman, T., Ziere, G., Lindemans, J., Klaver, C.C., Tiemeier, H., Stricker, B., Ikram, A.M., Laven, J.S., Brusselle, G.G., Rivadeneira, F., Franco, O.H.: Design of a frailty index among community living middle-aged and older people: The Rotterdam study. *Maturitas* **97**, 14–20 (2017). doi:[10.1016/j.maturitas.2016.12.002](https://doi.org/10.1016/j.maturitas.2016.12.002)
- Searle, S.D., Mitnitski, A., Gahbauer, E.A., Gill, T.M., Rockwood, K.: A standard procedure for creating a frailty index. *BMC Geriatr* **8**, 24 (2008). doi:[10.1186/1471-2318-8-24](https://doi.org/10.1186/1471-2318-8-24)


17. Lakschevitz, F.S., Hassanpour, S., Rubin, A., Fine, N., Sun, C., Glogauer, M.: Identification of neutrophil surface marker changes in health and inflammation using high-throughput screening flow cytometry. *Experimental Cell Research* **342**(2), 200–209 (2016). doi:[10.1016/j.yexcr.2016.03.007](https://doi.org/10.1016/j.yexcr.2016.03.007)
18. Fujimoto, H., Sakata, T., Hamaguchi, Y., Shiga, S., Tohyama, K., Ichiyama, S., Wang, F.-s., Houwen, B.: Flow cytometric method for enumeration and classification of reactive immature granulocyte populations. *Cytometry* **42**(6), 371–378 (2000). doi:[10.1002/1097-0320\(20001215\)42:6<371::AID-CYTO1004>3.0.CO;2-G](https://doi.org/10.1002/1097-0320(20001215)42:6<371::AID-CYTO1004>3.0.CO;2-G)
19. Riera, N., Canalejo, K., Aixalá, M., Rosso, M., Gaddi, E., de Bracco, M.M.d.E., Galassi, N.: Detection of CD16low neutrophil subpopulations. *Cytometry Part B: Clinical Cytometry* **51B**(1), 45–46 (2003). doi:[10.1002/cyto.b.10004](https://doi.org/10.1002/cyto.b.10004)
20. Kim, O., Monsel, A., Bertrand, M., Coriat, P., Cavillon, J.-M., Adib-Conquy, M.: Differential down-regulation of HLA-DR on monocyte subpopulations during systemic inflammation. *Critical Care* **14**(2), 61 (2010). doi:[10.1186/cc8959](https://doi.org/10.1186/cc8959)
21. Amici, S.A., Young, N.A., Narvaez-Miranda, J., Jablonski, K.A., Arcos, J., Rosas, L., Papenfuss, T.L., Torrelles, J.B., Jarjour, W.N., Guerau-de-Arellano, M.: CD38 Is Robustly Induced in Human Macrophages and Monocytes in Inflammatory Conditions. *Frontiers in Immunology* **9**, 1593 (2018). doi:[10.3389/fimmu.2018.01593](https://doi.org/10.3389/fimmu.2018.01593)
22. Michel, T., Poli, A., Cuapio, A., Briquemont, B., Iserentant, G., Ollert, M., Zimmer, J.: Human CD56^{bright} NK Cells: An Update. *The Journal of Immunology* **196**(7), 2923 (2016). doi:[10.4049/jimmunol.1502570](https://doi.org/10.4049/jimmunol.1502570)
23. Miyara, M., Yoshioka, Y., Kitoh, A., Shima, T., Wing, K., Niwa, A., Parizot, C., Taffin, C., Heike, T., Valeyre, D., Mathian, A., Nakahata, T., Yamaguchi, T., Nomura, T., Ono, M., Amoura, Z., Gorochov, G., Sakaguchi, S.: Functional delineation and differentiation dynamics of human CD4⁺ T cells expressing the FoxP3 transcription factor. *Immunity* **30**(6), 899–911 (2009). doi:[10.1016/j.immuni.2009.03.019](https://doi.org/10.1016/j.immuni.2009.03.019)
24. van den Heuvel, D., Jansen, M.A.E., Nasserinejad, K., Dik, W.A., van Lochem, E.G., Bakker-Jonges, L.E., Bouallouch-Charif, H., Jaddoe, V.W.V., Hooijkaas, H., van Dongen, J.J.M., Moll, H.A., van Zelm, M.C.: Effects of nongenetic factors on immune cell dynamics in early childhood: The Generation R Study. *Journal of Allergy and Clinical Immunology* **139**(6), 1923–1934 (2017). doi:[10.1016/j.jaci.2016.10.023](https://doi.org/10.1016/j.jaci.2016.10.023)
25. van der Heiden, M., van Zelm, M.C., Bartol, S.J., de Rond, L.G., Berbers, G.A., Boots, A.M., Buisman, A.M.: Differential effects of Cytomegalovirus carriage on the immune phenotype of middle-aged males and females. *Sci Rep* **6**, 26892 (2016). doi:[10.1038/srep26892](https://doi.org/10.1038/srep26892)
26. Tcherniaeva, I., den Hartog, G., Berbers, G., van der Klis, F.: The development of a bead-based multiplex immunoassay for the detection of IgG antibodies to CMV and EBV. *J Immunol Methods* **462**, 1–8 (2018). doi:[10.1016/j.jim.2018.07.003](https://doi.org/10.1016/j.jim.2018.07.003)
27. Loef, B., van Baarle, D., van der Beek, A.J., van Kerkhof, L.W., van de Langenberg, D., Proper, K.I.: Klokwerk + study protocol: An observational study to the effects of night-shift work on body weight and infection susceptibility and the mechanisms underlying these health effects. *BMC Public Health* **16**(1), 692 (2016). doi:[10.1186/s12889-016-3317-1](https://doi.org/10.1186/s12889-016-3317-1)
28. van Beek, J., Veenhoven, R.H., Bruin, J.P., van Boxtel, R.A.J., de Lange, M.M.A., Meijer, A., Sanders, E.A.M., Rots, N.Y., Luytjes, W.: Influenza-like Illness Incidence Is Not Reduced by Influenza Vaccination in a Cohort of Older Adults, Despite Effectively Reducing Laboratory-Confirmed Influenza Virus Infections. *The Journal of Infectious Diseases* **216**(4), 415–424 (2017). doi:[10.1093/infdis/jix268](https://doi.org/10.1093/infdis/jix268)
29. Verberk, J.D.M., Vos, R.A., Mollema, L., van Vliet, J., van Weert, J.W.M., de Melker, H.E., van der Klis, F.R.M.: Third national biobank for population-based seroprevalence studies in the Netherlands, including the Caribbean Netherlands. *BMC Infectious Diseases* **19**(1), 470 (2019). doi:[10.1186/s12879-019-4019-y](https://doi.org/10.1186/s12879-019-4019-y)
30. Benaglia, T., Chauveau, D., Hunter, D.R., Young, D.: Mixtools : An R Package for Analyzing Finite Mixture Models. *Journal of Statistical Software* **32**(6) (2009). doi:[10.18637/jss.v032.i06](https://doi.org/10.18637/jss.v032.i06)
31. van Lier, A., Smits, G., Mollema, L., Waaijenborg, S., Berbers, G., van der Klis, F., Boot, H., Wallinga, J., de Melker, H.: Varicella zoster virus infection occurs at a relatively young age in the Netherlands. *Vaccine* **31**(44), 5127–5133 (2013/10/17/). doi:[10.1016/j.vaccine.2013.08.029](https://doi.org/10.1016/j.vaccine.2013.08.029)
32. Benjamini, Y., Hochberg, Y.: Controlling the false discovery rate: A practical and powerful approach to multiple testing. *Journal of the Royal Statistical Society. Series B (Methodological)* **57**(1), 289–300 (1995). doi:[10.2307/2346101](https://doi.org/10.2307/2346101)
33. Hothorn, T., Hornik, K., van de Wiel, M.A., Zeileis, A.: Implementing a Class of Permutation Tests: The coin Package. *Journal of Statistical Software* **28**(8) (2008). doi:[10.18637/jss.v028.i08](https://doi.org/10.18637/jss.v028.i08)
34. Hothorn, T., Hornik, K., van de Wiel, M.A., Zeileis, A.: A Lego System for Conditional Inference. *The American Statistician* **60**(3), 257–263 (2006). doi:[10.1198/000313006X118430](https://doi.org/10.1198/000313006X118430)
35. Liaw, A., Wiener, M.: Classification and regression by randomForest. *R News* **2**(3), 18–22 (2002)
36. Greenwell, B.M.: Pdp: An R package for constructing partial dependence plots. *The R Journal* **9**(1), 421–436 (2017)

37. Breiman, L.: Random Forests. *Machine Learning* **45**(1), 5–32 (2001). doi:[10.1023/A:1010933404324](https://doi.org/10.1023/A:1010933404324)
38. Knights, D., Costello, E.K., Knight, R.: Supervised classification of human microbiota. *FEMS Microbiology Reviews* **35**(2), 343–359 (2011). doi:[10.1111/j.1574-6976.2010.00251.x](https://doi.org/10.1111/j.1574-6976.2010.00251.x)
39. Lee, J.W., Lee, J.B., Park, M., Song, S.H.: An extensive comparison of recent classification tools applied to microarray data. *Computational Statistics & Data Analysis* **48**(4), 869–885 (2005). doi:[10.1016/j.csda.2004.03.017](https://doi.org/10.1016/j.csda.2004.03.017)
40. Shrestha, A., Bergquist, S., Montz, E., Rose, S.: Mental Health Risk Adjustment with Clinical Categories and Machine Learning. *Health Services Research* **53**, 3189–3206 (2018). doi:[10.1111/1475-6773.12818](https://doi.org/10.1111/1475-6773.12818)
41. Konstantinides, N., Kapuralin, K., Fadil, C., Barboza, L., Satija, R., Desplan, C.: Phenotypic Convergence: Distinct Transcription Factors Regulate Common Terminal Features. *Cell* **174**(3), 622–63513 (2018). doi:[10.1016/j.cell.2018.05.021](https://doi.org/10.1016/j.cell.2018.05.021)
42. Karlsson, F.H., Tremaroli, V., Nookaew, I., Bergström, G., Behre, C.J., Fagerberg, B., Nielsen, J., Bäckhed, F.: Gut metagenome in European women with normal, impaired and diabetic glucose control. *Nature* **498**(7452), 99–103 (2013). doi:[10.1038/nature12198](https://doi.org/10.1038/nature12198)
43. Mukherjee, R., Kanti Barman, P., Kumar Thatoi, P., Tripathy, R., Kumar Das, B., Ravindran, B.: Non-Classical monocytes display inflammatory features: Validation in Sepsis and Systemic Lupus Erythematosus. *Scientific Reports* **5**, 13886 (2015)
44. Patel, A.A., Zhang, Y., Fullerton, J.N., Boelen, L., Rongvaux, A., Maini, A.A., Bigley, V., Flavell, R.A., Gilroy, D.W., Asquith, B., Macallan, D., Yona, S.: The fate and lifespan of human monocyte subsets in steady state and systemic inflammation. *The Journal of Experimental Medicine* **214**(7), 1913–1923 (2017). doi:[10.1084/jem.20170355](https://doi.org/10.1084/jem.20170355)
45. Ong, S.-M., Hadadi, E., Dang, T.-M., Yeap, W.-H., Tan, C.T.-Y., Ng, T.-P., Larbi, A., Wong, S.-C.: The pro-inflammatory phenotype of the human non-classical monocyte subset is attributed to senescence. *Cell Death & Disease* **9**(3), 266 (2018). doi:[10.1038/s41419-018-0327-1](https://doi.org/10.1038/s41419-018-0327-1)
46. Narasimhan, P.B., Marcovecchio, P., Hamers, A.A.J., Hedrick, C.C.: Nonclassical Monocytes in Health and Disease. *Annual Review of Immunology* **37**(1), 439–456 (2019). doi:[10.1146/annurev-immunol-042617-053119](https://doi.org/10.1146/annurev-immunol-042617-053119)
47. Buscher, K., Marcovecchio, P., Hedrick, C.C., Ley, K.: Patrolling Mechanics of Non-Classical Monocytes in Vascular Inflammation. *Frontiers in Cardiovascular Medicine* **4**, 80 (2017). doi:[10.3389/fcvm.2017.00080](https://doi.org/10.3389/fcvm.2017.00080)
48. Puchner, A., Saferding, V., Bonelli, M., Mikami, Y., Hofmann, M., Brunner, J.S., Caldera, M., Goncalves-Alves, E., Binder, N.B., Fischer, A., Simader, E., Steiner, C.-W., Leiss, H., Hayer, S., Niederreiter, B., Karonitsch, T., Koenders, M.I., Podesser, B.K., O'Shea, J.J., Menche, J., Smolen, J.S., Redlich, K., Blüml, S.: Non-classical monocytes as mediators of tissue destruction in arthritis. *Annals of the Rheumatic Diseases*, 2018–213250 (2018). doi:[10.1136/annrheumdis-2018-213250](https://doi.org/10.1136/annrheumdis-2018-213250)
49. Fairweather, D.: Sex Differences in Inflammation during Atherosclerosis. *Clinical Medicine Insights: Cardiology* **8s3**, 17068 (2014). doi:[10.4137/CMC.S17068](https://doi.org/10.4137/CMC.S17068)
50. Michel, J.J., Griffin, P., Vallejo, A.N.: Functionally Diverse NK-Like T Cells Are Effectors and Predictors of Successful Aging. *Frontiers in Immunology* **7** (2016). doi:[10.3389/fimmu.2016.00530](https://doi.org/10.3389/fimmu.2016.00530)
51. Nevalainen, T., Autio, A., Kummola, L., Salomaa, T., Junttila, I., Jylhä, M., Hurme, M.: CD27- IgD- B cell memory subset associates with inflammation and frailty in elderly individuals but only in males. *Immunity & Ageing* **16**(1), 19 (2019). doi:[10.1186/s12979-019-0159-6](https://doi.org/10.1186/s12979-019-0159-6)
52. Gordon, E.H., Hubbard, R.E.: Do sex differences in chronic disease underpin the sex-frailty paradox? *Mechanisms of Ageing and Development* **179**, 44–50 (2019). doi:[10.1016/j.mad.2019.02.004](https://doi.org/10.1016/j.mad.2019.02.004)
53. Leng, S.X., Xue, Q.L., Tian, J., Huang, Y., Yeh, S.H., Fried, L.P.: Associations of neutrophil and monocyte counts with frailty in community-dwelling disabled older women: Results from the Women's Health and Aging Studies I. *Exp Gerontol* **44**(8), 511–6 (2009). doi:[10.1016/j.exger.2009.05.005](https://doi.org/10.1016/j.exger.2009.05.005)
54. Tang, B.M., Shojaei, M., Teoh, S., Meyers, A., Ho, J., Ball, T.B., Keynan, Y., Pisipati, A., Kumar, A., Eisen, D.P., Lai, K., Gillett, M., Santram, R., Geffers, R., Schreiber, J., Mozhui, K., Huang, S., Parnell, G.P., Nalos, M., Holubova, M., Chew, T., Booth, D., Kumar, A., McLean, A., Schughart, K.: Neutrophils-related host factors associated with severe disease and fatality in patients with influenza infection. *Nature Communications* **10**(1), 3422 (2019). doi:[10.1038/s41467-019-11249-y](https://doi.org/10.1038/s41467-019-11249-y)
55. Leins, H., Mulaw, M., Eiwien, K., Sakk, V., Liang, Y., Denking, M., Geiger, H., Schirmbeck, R.: Aged murine hematopoietic stem cells drive aging-associated immune remodeling. *Blood* **132**(6), 565–576 (2018). doi:[10.1182/blood-2018-02-831065](https://doi.org/10.1182/blood-2018-02-831065). <http://www.bloodjournal.org/content/132/6/565.full.pdf>
56. Kovtonyuk, L.V., Fritsch, K., Feng, X., Manz, M.G., Takizawa, H.: Inflamm-Aging of Hematopoiesis, Hematopoietic Stem Cells, and the Bone Marrow Microenvironment. *Front Immunol* **7**(502), 502 (2016). doi:[10.3389/fimmu.2016.00502](https://doi.org/10.3389/fimmu.2016.00502)

57. Pioli, P.D., Casero, D., Montecino-Rodriguez, E., Morrison, S.L., Dorshkind, K.: Plasma Cells Are Obligate Effectors of Enhanced Myelopoiesis in Aging Bone Marrow. *Immunity* **51**(2), 351–366 (2019). doi:[10.1016/j.immuni.2019.06.006](https://doi.org/10.1016/j.immuni.2019.06.006)
58. Soysal, P., Stubbs, B., Lucato, P., Luchini, C., Solmi, M., Peluso, R., Sergi, G., Isik, A.T., Manzato, E., Maggi, S., Maggio, M., Prina, A.M., Cosco, T.D., Wu, Y.T., Veronese, N.: Inflammation and frailty in the elderly: A systematic review and meta-analysis. *Ageing Res Rev* **31**, 1–8 (2016). doi:[10.1016/j.arr.2016.08.006](https://doi.org/10.1016/j.arr.2016.08.006)
59. van Lier, R.A.W., Kuijpers, T.W.: The cellular immune system comes of age. *Journal of Allergy and Clinical Immunology* **139**(6), 1793–1794 (2017). doi:[10.1016/j.jaci.2017.02.023](https://doi.org/10.1016/j.jaci.2017.02.023)
60. Li, M., Yao, D., Zeng, X., Kasakovski, D., Zhang, Y., Chen, S., Zha, X., Li, Y., Xu, L.: Age related human T cell subset evolution and senescence. *Immunity & Ageing* **16**(1), 24 (2019). doi:[10.1186/s12979-019-0165-8](https://doi.org/10.1186/s12979-019-0165-8)
61. Saule, P., Trauet, J., Dutriez, V., Lekeux, V., Dessaint, J.-P., Labalette, M.: Accumulation of memory T cells from childhood to old age: Central and effector memory cells in CD4+ versus effector memory and terminally differentiated memory cells in CD8+ compartment. *Mechanisms of Ageing and Development* **127**(3), 274–281 (2006). doi:[10.1016/j.mad.2005.11.001](https://doi.org/10.1016/j.mad.2005.11.001)
62. Ng, T.P., Camous, X., Nyunt, M.S.Z., Vasudev, A., Tan, C.T.Y., Feng, L., Fulop, T., Yap, K.B., Larbi, A.: Markers of T-cell senescence and physical frailty: Insights from Singapore Longitudinal Ageing Studies. *NPJ aging and mechanisms of disease* **1**, 15005–15005 (2015). doi:[10.1038/npjamd.2015.5](https://doi.org/10.1038/npjamd.2015.5)
63. Schmalz, H.N., Fried, L.P., Xue, Q.-L., Walston, J., Leng, S.X., Semba, R.D.: Chronic Cytomegalovirus Infection and Inflammation Are Associated with Prevalent Frailty in Community-Dwelling Older Women **53**(5), 747–754 (2005). doi:[10.1111/j.1532-5415.2005.53250.x](https://doi.org/10.1111/j.1532-5415.2005.53250.x)
64. Wang, G.C., Kao, W.H.L., Murakami, P., Xue, Q.-L., Chiou, R.B., Detrick, B., McDyer, J.F., Semba, R.D., Casolaro, V., Walston, J.D., Fried, L.P.: Cytomegalovirus Infection and the Risk of Mortality and Frailty in Older Women: A Prospective Observational Cohort Study. *American Journal of Epidemiology* **171**(10), 1144–1152 (2010). doi:[10.1093/aje/kwq062](https://doi.org/10.1093/aje/kwq062)
65. Matheï, C., Vaes, B., Wallemacq, P., Degryse, J.: Associations Between Cytomegalovirus Infection and Functional Impairment and Frailty in the BELFRAIL Cohort. *Journal of the American Geriatrics Society* **59**(12), 2201–2208 (2011). doi:[10.1111/j.1532-5415.2011.03719.x](https://doi.org/10.1111/j.1532-5415.2011.03719.x)
66. Bupp, M.R.G.: Sex, the aging immune system, and chronic disease. *Cellular Immunology* **294**(2), 102–110 (2015). doi:[10.1016/j.cellimm.2015.02.002](https://doi.org/10.1016/j.cellimm.2015.02.002). Sex Disparity in Immune Responses
67. Pennell, L.M., Galligan, C.L., Fish, E.N.: Sex affects immunity. *Journal of Autoimmunity* **38**(2-3), 282–291 (2012). doi:[10.1016/j.jaut.2011.11.013](https://doi.org/10.1016/j.jaut.2011.11.013)
68. Fried, L.P., Tangen, C.M., Walston, J., Newman, A.B., Hirsch, C., Gottdiener, J., Seeman, T., Tracy, R., Kop, W.J., Burke, G., McBurnie, M.A.: Cardiovascular Health Study Collaborative Research, G.: Frailty in older adults: Evidence for a phenotype. *J Gerontol A Biol Sci Med Sci* **56**(3), 146–56 (2001). doi:[10.1093/gerona/56.3.M146](https://doi.org/10.1093/gerona/56.3.M146)

Figures**Tables****Additional Files**

Additional file 1 — Supplementary Figures S1-S3 and Tables S1-S4









Figure 2 The numbers of cells per leukocyte subpopulations in men (n=145) and women (n=144) above 60 years of age. The boxplots show median values with interquartile range. CM: central memory (CD4 or CD8 positive) T cells. Tem: effector memory (CD4 or CD8 positive) T cells. TemRA: effector memory T cells re-expressing CD45RA. *: Outcomes of tests of the association between leukocyte numbers and sex (adjusted for age and CMV serostatus) which passed the Benjamini-Hochberg method at a false discovery rate of 15%.









Figure S1 General gating strategy showing gating of single cells by FSC-A versus FSC-H, leukocyte subsets by SSC and CD45, monocyte subpopulations by CD16, T and B-cells by CD3 and CD19, and NK cells by CD16 and CD56.






Table S1 Definition of cell phenotypes by expression of cell surface markers

Cell phenotype	Definition
T cells	
T cells	CD45 ⁺ CD3 ⁺
T Follicular helper	CD3 ⁺ CD4 ⁺ CD45RA ⁻ CXCR5 ⁺
CD56 ⁺ T cells	CD45 ⁺ CD3 ⁺ CD56 ⁺
CD4/CD8 ratio	CD4 T cells/CD8 T cells
CD4 T cells	CD45 ⁺ CD3 ⁺ CD4 ⁺
CD4 Naive	CD3 ⁺ CD4 ⁺ CD45RA ⁺ CCR7 ⁺
CD4 CM	CD3 ⁺ CD4 ⁺ CD45RA ⁻ CCR7 ⁺
CD4 TemRA	CD3 ⁺ CD4 ⁺ CD45RA ⁺ CCR7 ⁻
CD4 TemRA Early	CD3 ⁺ CD4 ⁺ CD45RA ⁺ CCR7 ⁻ CD27 ⁺ CD28 ⁺
CD4 TemRA Late	CD3 ⁺ CD4 ⁺ CD45RA ⁺ CCR7 ⁻ CD27 ⁻ CD28 ⁻
CD4 Tem	CD3 ⁺ CD4 ⁺ CD45RA ⁻ CCR7 ⁻
CD4 Tem Early	CD3 ⁺ CD4 ⁺ CD45RA ⁻ CCR7 ⁻ CD27 ⁺ CD28 ⁺
CD4 Tem Late	CD3 ⁺ CD4 ⁺ CD45RA ⁻ CCR7 ⁻ CD27 ⁻ CD28 ⁻
Regulatory T cells	CD3 ⁺ CD4 ⁺ CD25 ^{BRIGHT}
Treg naive	CD3 ⁺ CD4 ⁺ CD25 ^{BRIGHT} CD45RA ⁺
Treg memory	CD3 ⁺ CD4 ⁺ CD25 ^{BRIGHT} CD45RA ⁻
CD8 T cells	CD45 ⁺ CD3 ⁺ CD8 ⁺
CD8 Naive	CD3 ⁺ CD8 ⁺ CD45RA ⁺ CCR7 ⁺
CD8 CM	CD3 ⁺ CD8 ⁺ CD45RA ⁻ CCR7 ⁺
CD8 TemRA	CD3 ⁺ CD8 ⁺ CD45RA ⁺ CCR7 ⁻
CD8 TemRA Early	CD3 ⁺ CD8 ⁺ CD45RA ⁺ CCR7 ⁻ CD27 ⁺ CD28 ⁺
CD8 TemRA Late	CD3 ⁺ CD8 ⁺ CD45RA ⁺ CCR7 ⁻ CD27 ⁻ CD28 ⁻
CD8 Tem	CD3 ⁺ CD8 ⁺ CD45RA ⁻ CCR7 ⁻
CD8 Tem Early	CD3 ⁺ CD8 ⁺ CD45RA ⁻ CCR7 ⁻ CD27 ⁺ CD28 ⁺
CD8 Tem Late	CD3 ⁺ CD8 ⁺ CD45RA ⁻ CCR7 ⁻ CD27 ⁻ CD28 ⁻
Neutrophils	
Neutrophils	SSC ^{BRIGHT} CD45 ^{DIM}
Neutrophils, CD16 expr.	SSC ^{BRIGHT} CD45 ^{DIM} ;CD16 ^{expression}
Monocytes	
Monocytes	SSC ^{DIM} CD45 ⁺ CD3 ⁻ CD19 ⁻
CD16 ⁻ monocytes	SSC ^{DIM} CD45 ⁺ CD16 ⁻
CD16 ⁻ mon. CD38 expr.	SSC ^{DIM} CD45 ⁺ CD16 ⁻ ;CD38 ^{expression}
CD16 ⁻ mon. HLADR expr.	SSC ^{DIM} CD45 ⁺ CD16 ⁻ ;HLADR ^{expression}
CD16 ⁺ monocytes	SSC ^{DIM} CD45 ⁺ CD16 ⁺
CD16 ⁺ mon. CD38 expr.	SSC ^{DIM} CD45 ⁺ CD16 ⁺ ;CD38 ^{expression}
CD16 ⁺ mon. HLADR expr.	SSC ^{DIM} CD45 ⁺ CD16 ⁺ ;HLADR ^{expression}
B cells	
B cells	CD45 ⁺ CD19 ⁺
Plasmablasts	CD45 ⁺ CD19 ⁺ CD38 ^{BRIGHT} CD27 ^{BRIGHT}
Transitional B cells	CD45 ⁺ CD19 ⁺ CD38 ^{BRIGHT} CD27 ⁻
Naive B cells	CD45 ⁺ CD19 ⁺ CD38 ^{DIM} CD27 ⁻
Memory B cells	CD45 ⁺ CD19 ⁺ CD38 ^{DIM} CD27 ⁺
NK cells	
NK cells	Either NK CD56 ^{BRIGHT} or NK CD56 ^{DIM}
NK CD56 ^{BRIGHT}	CD45 ⁺ CD3 ⁻ CD19 ⁻ CD16 ^{DIM} CD56 ^{BRIGHT}
NK CD56 ^{DIM}	CD45 ⁺ CD3 ⁻ CD19 ⁻ CD16 ^{BRIGHT} CD56 ^{DIM}

Table S2 Leukocyte numbers per sex and CMV serostatus

	Men			Women		
	CMV- (n=69)	CMV+ (n=76)	P value ¹	CMV- (n=53)	CMV+ (n=91)	P value ¹
T cells						
T cells	1002.6 (428.9)	1202.5 (463.4)	<0.001*	1144.7 (436.2)	1272.4 (474.9)	0.026*
T Follicular helper	49.5 (28.8)	61.8 (34.1)	0.04*	67.5 (37.6)	66.7 (40.9)	0.374
CD56 ⁺ T cells	21.8 (27.8)	60.9 (108.5)	<0.001*	16 (16.7)	48.5 (61.9)	<0.001*
CD4/CD8 ratio	3.6 (2.7)	2.5 (1.8)	0.002*	4.2 (3.2)	2.8 (1.7)	<0.001*
CD4 T cells	669.7 (370.9)	766.5 (391.6)	0.041*	897.3 (371.9)	892.2 (363.3)	0.847
CD4 Naive	316.3 (283.4)	243.1 (215.2)	0.292	343.7 (262)	374.6 (295.9)	0.924
CD4 CM	175.6 (90.3)	217.1 (105)	0.01*	234.1 (118)	230.9 (149.4)	0.179
CD4 TemRA	27.8 (28.8)	46.7 (45.7)	<0.001*	33.9 (50.7)	52.6 (52.4)	0.003*
CD4 TemRA Early	22.4 (26.5)	19.7 (21.2)	0.666	29.7 (44.1)	28.2 (32.2)	0.839
CD4 TemRA Late	0.1 (0.2)	5.4 (24.2)	<0.001*	0.1 (0.2)	5.9 (13.9)	<0.001*
CD4 Tem	110.6 (70.1)	153.8 (108.3)	<0.001*	155.8 (91.6)	179.9 (112.8)	0.177
CD4 Tem Early	77.7 (51.5)	86.9 (54.3)	0.166	114.7 (59.8)	106 (73.2)	0.362
CD4 Tem Late	1.1 (1.5)	15 (25.5)	<0.001*	1.1 (1.6)	8.9 (14.2)	<0.001*
Regulatory T cells	34 (18.8)	34.7 (23.8)	0.556	42.6 (22.8)	42.1 (26.5)	0.377
Treg naive	6.7 (4.1)	7.2 (3.2)	0.607	8.3 (6.4)	9.4 (5.7)	0.479
Treg memory	9.3 (5.8)	10.2 (5.2)	0.343	10.5 (5.6)	9.1 (6.4)	0.049
CD8 T cells	188.9 (198.7)	337.2 (246.1)	<0.001*	203.5 (124.1)	333.2 (159.1)	<0.001*
CD8 Naive	20 (31.5)	18 (26.4)	0.532	35.4 (41.9)	34.1 (33.8)	0.948
CD8 CM	13.7 (11.7)	17.3 (15.6)	0.01*	17.3 (14)	16.8 (15.3)	0.76
CD8 TemRA	32.3 (36.9)	83.6 (109.9)	<0.001*	27.8 (26.9)	75 (74)	<0.001*
CD8 TemRA Early	6.3 (7.8)	7.4 (8.4)	0.73	6.7 (7.5)	9.1 (9.3)	0.129
CD8 TemRA Late	10.5 (16.1)	54.1 (66.2)	<0.001*	8.6 (13)	40.4 (49.1)	<0.001*
CD8 Tem	120.1 (116.9)	227.9 (135.7)	<0.001*	117.4 (62.9)	212.4 (111.9)	<0.001*
CD8 Tem Early	64.3 (63.6)	73 (68.1)	0.409	74.7 (53.3)	88.6 (59.3)	0.538
CD8 Tem Late	11.4 (14.5)	59 (72.8)	<0.001*	6.6 (7.8)	48.9 (55.5)	<0.001*
Neutrophils						
Neutrophils	2811.5 (2204.9)	2646.3 (1309.4)	0.197	2707.9 (1478.6)	2851.3 (1573.1)	0.733
Neutrophils, CD16 expr. ²	3671 (5564)	3971 (5900.2)	0.393	3950 (5273)	4343 (5299)	0.86
Monocytes						
Monocytes	276.5 (136.6)	246.5 (126.3)	0.057*	233.4 (144.2)	218.4 (125.2)	0.365
CD16 ⁻ monocytes	273.2 (134.9)	246 (122.1)	0.064*	229.3 (143)	211.8 (125.8)	0.351
CD16 ⁻ mon. CD38 expr.	1200.5 (338.2)	1273 (341.5)	0.039*	1168 (193)	1216 (285)	0.401
CD16 ⁻ mon. HLADR expr.	9106 (6090.2)	8736 (4603)	0.78	8834 (3806)	8171 (6208)	0.907
CD16 ⁺ monocytes	4 (4.7)	4 (3.9)	0.397	4 (3.8)	3.4 (4.2)	0.628
CD16 ⁺ mon. CD38 expr.	445.5 (192.5)	499 (199.5)	0.157	412 (139)	444 (218)	0.138
CD16 ⁺ mon. HLADR expr.	56851 (27956)	52916 (41323.5)	0.587	42036 (41637)	39669 (39328)	0.935
B cells						
B cells	124 (86.8)	150.4 (104.2)	0.427	167.7 (115.2)	173.9 (118.8)	0.904
Plasmablasts	1.5 (1.5)	1.4 (1.4)	0.677	1.5 (1.5)	1.4 (1.2)	0.644
Transitional B cells	3.7 (3.7)	3.8 (5.6)	0.643	4.6 (4.8)	4.2 (4.4)	0.806
Naive B cells	92.1 (72.8)	111 (75.6)	0.487	124.8 (88.9)	120.4 (78.1)	0.826
Memory B cells	24 (24.4)	28.4 (30)	0.73	32.8 (33.4)	37.1 (32.2)	0.667
NK cells						
NK cells	274.9 (217)	217.4 (191.2)	0.109	236.1 (117)	212.3 (138.8)	0.39
NK CD56 ^{BRIGHT}	10.7 (7.2)	10.4 (7.7)	0.872	11.6 (8.9)	9.9 (6.6)	0.199
NK CD56 ^{DIM}	251 (219.4)	203.1 (183.8)	0.116	220.8 (109.8)	204.6 (139.5)	0.46

Note:

All values are median (interquartile range) cell numbers per μL , unless otherwise stated

¹ P values of Kruskal-Wallis rank sum test between CMV serostatus per sex, adjusted for age

² Values in Median fluorescence intensity

* Selected outcomes when the False Discovery Rate is set to a maximum of 15%

Table S3 Spearman associations between immune cell subpopulations and frailty in men (n=140)

Immune cell subset	Spearman's rho	P value	FDR*
Neutrophils	0.245	0.002	0.077
Transitional B cells	-0.188	0.015	0.324
Monocytes	0.166	0.027	0.389
CD16 ⁻ monocytes	0.155	0.036	0.383
CD4 Naive	0.172	0.040	0.341
CD4 TemRA Late	0.129	0.078	0.562
CD4 TemRA	0.166	0.090	0.553
Regulatory T cells	0.122	0.104	0.561
CD16 ⁺ monocytes	0.162	0.133	0.634
CD16 ⁻ mon. HLADR expr.	-0.145	0.133	0.571
NK CD56 ^{DIM}	-0.079	0.172	0.672
CD4 TemRA Early	0.136	0.191	0.686
CD4 T cells	0.088	0.207	0.683
NK cells	-0.061	0.208	0.638
CD4/CD8 ratio	0.103	0.219	0.628
Memory B cells	-0.072	0.319	0.857
T cells	0.087	0.321	0.812
CD8 Tem Early	-0.067	0.354	0.844
Treg naive	0.077	0.387	0.877
Neutrophils, CD16 expr.	-0.098	0.399	0.858
T Follicular helper	0.070	0.439	0.898
CD16 ⁺ mon. CD38 expr.	-0.049	0.440	0.860
Lymphocytes	0.037	0.574	1.073
NK CD56 ^{BRIGHT}	-0.026	0.582	1.042
CD8 Naive	0.053	0.590	1.014
CD8 CM	-0.049	0.650	1.074
CD8 T cells	0.027	0.658	1.048
B cells	-0.056	0.667	1.025
CD8 Tem Late	0.091	0.689	1.022
CD56 ⁺ T cells	0.027	0.694	0.995
CD8 Tem	0.015	0.697	0.967
CD16 ⁻ mon. CD38 expr.	-0.005	0.705	0.948
CD16 ⁺ mon. HLADR expr.	0.071	0.728	0.949
CD4 Tem Late	0.033	0.735	0.930
CD4 CM	-0.051	0.757	0.931
CD4 Tem Early	-0.030	0.789	0.943
CD8 TemRA Late	0.021	0.796	0.925
Plasmablasts	0.040	0.810	0.916
Naive B cells	-0.052	0.839	0.925
CD8 TemRA	0.023	0.851	0.915
CD8 TemRA Early	-0.010	0.931	0.976
Treg memory	0.028	0.967	0.990
CD4 Tem	0.003	0.994	0.994

Note:

The (Spearman) associations are ordered by p value, with the lowest p values shown at the top. Associations that were selected with a FDR lower than 15% are shown in bold.

* False Discovery Rate (estimated)

Table S4 Spearman associations between immune cell subpopulations and frailty in women (n=137)

Immune cell subset	Spearman's rho	P value	FDR*
Neutrophils	0.399	<0.001	0.000
CD16⁻ monocytes	0.237	0.003	0.066
Monocytes	0.234	0.004	0.054
CD56⁺ T cells	-0.198	0.01	0.109
CD4 TemRA Late	-0.131	0.015	0.128
CD16 ⁻ mon. CD38 expr.	-0.199	0.022	0.157
CD4 Tem Early	0.205	0.032	0.194
CD16 ⁺ mon. CD38 expr.	-0.184	0.037	0.200
CD16 ⁻ mon. HLADR expr.	-0.116	0.063	0.302
CD4 Tem	0.153	0.073	0.313
NK CD56 ^{BRIGHT}	-0.150	0.08	0.311
CD8 TemRA	-0.094	0.091	0.325
Transitional B cells	-0.164	0.096	0.318
CD8 TemRA Late	-0.079	0.099	0.303
NK CD56 ^{DIM}	-0.152	0.133	0.382
NK cells	-0.133	0.149	0.401
CD8 CM	0.145	0.165	0.418
CD4 Tem Late	-0.042	0.235	0.562
CD4/CD8 ratio	0.112	0.25	0.567
CD4 TemRA Early	0.093	0.274	0.589
CD8 T cells	-0.102	0.322	0.658
CD4 CM	0.074	0.34	0.665
CD4 Naive	-0.112	0.344	0.643
T Follicular helper	0.088	0.347	0.621
CD8 Naive	-0.128	0.359	0.618
Treg memory	0.075	0.374	0.618
CD8 TemRA Early	-0.020	0.422	0.672
Memory B cells	-0.093	0.428	0.658
Plasmablasts	-0.071	0.461	0.683
T cells	-0.045	0.49	0.702
CD8 Tem Early	0.121	0.519	0.720
Lymphocytes	-0.023	0.526	0.707
CD16 ⁺ monocytes	0.071	0.551	0.718
B cells	-0.061	0.579	0.732
Neutrophils, CD16 expr.	-0.006	0.73	0.897
Treg naive	-0.039	0.779	0.930
CD8 Tem	0.018	0.814	0.946
CD4 TemRA	0.002	0.913	1.033
CD16 ⁺ mon. HLADR expr.	0.014	0.946	1.044
CD8 Tem Late	0.010	0.953	1.025
Regulatory T cells	0.012	0.966	1.013
CD4 T cells	0.012	0.967	0.990
Naive B cells	0.002	0.984	0.984

Note:

The (Spearman) associations are ordered by p value, with the lowest p values shown at the top. Associations that were selected with a FDR lower than 15% are shown in bold.

* False Discovery Rate (estimated)

Table S5 Additional analysis in men (n=140) to test associations with frailty when percentages of subpopulations are used instead of absolute numbers

Immune cell subset	Spearman's rho	P value	FDR*
Transitional B cells, (%)	-0.218	0.011	0.373
CD4 Naive, (%)	0.223	0.018	0.302
CD4 CM, (%)	-0.242	0.023	0.260
T cells, (%)	0.159	0.047	0.395
NK cells, (%)	-0.112	0.091	0.621
CD4 TemRA Late, (%)	0.111	0.169	0.958
B cells, (%)	-0.139	0.181	0.880
NK CD56 ^{BRIGHT} , (%)	0.101	0.185	0.787
CD4 Tem, (%)	-0.095	0.186	0.702
CD4 Tem Early, (%)	-0.109	0.204	0.695
CD8 T cells, (%)	-0.110	0.209	0.644
CD4 T cells, (%)	0.116	0.213	0.603
Treg memory, (%)	-0.087	0.215	0.562
NK CD56 ^{DIM} , (%)	-0.080	0.247	0.600
CD4 TemRA, (%)	0.097	0.260	0.589
CD8 Naive, (%)	0.076	0.342	0.727
Regulatory T cells, (%)	0.049	0.425	0.849
CD8 CM, (%)	-0.033	0.464	0.877
CD8 Tem Early, (%)	-0.073	0.469	0.840
CD8 Tem Late, (%)	0.111	0.474	0.806
CD4 TemRA Early, (%)	0.055	0.573	0.927
Plasmablasts, (%)	0.043	0.582	0.900
Memory B cells, (%)	-0.012	0.670	0.990
CD8 TemRA, (%)	0.029	0.676	0.958
Naive B cells, (%)	0.012	0.705	0.958
CD8 TemRA Late, (%)	0.004	0.719	0.940
CD8 TemRA Early, (%)	-0.003	0.769	0.969
T Follicular helper, (%)	-0.032	0.793	0.963
CD16 ⁻ monocytes, (%)	0.009	0.838	0.983
CD4 Tem Late, (%)	-0.046	0.848	0.961
CD8 Tem, (%)	0.078	0.865	0.948
CD16 ⁺ monocytes, (%)	-0.006	0.890	0.945
Treg naive, (%)	-0.025	0.934	0.962
CD56 ⁺ T cells, (%)	-0.032	0.992	0.992

Note:

The (Spearman) associations are ordered by p value, with the lowest p values shown at the top. Associations that were selected with a FDR lower than 15% are shown in bold

* False Discovery Rate (estimated)

Table S6 Additional analysis in women (n=137) to test associations with frailty when percentages of subpopulations are used instead of absolute numbers

Immune cell subset	Spearman's rho	P value	FDR*
CD56 ⁺ T cells, (%)	-0.178	0.009	0.304
CD4 TemRA Late, (%)	-0.173	0.009	0.156
CD8 Tem, (%)	0.196	0.021	0.236
Transitional B cells, (%)	-0.207	0.022	0.188
CD4 Tem Early, (%)	0.173	0.029	0.195
CD8 Tem Early, (%)	0.176	0.056	0.319
CD8 CM, (%)	0.142	0.062	0.301
CD8 TemRA Late, (%)	-0.088	0.065	0.275
CD4 Tem, (%)	0.155	0.066	0.251
CD8 TemRA, (%)	-0.089	0.075	0.256
Naive B cells, (%)	0.131	0.086	0.264
NK cells, (%)	-0.167	0.093	0.264
CD4 Naive, (%)	-0.121	0.133	0.347
CD4 CM, (%)	0.137	0.138	0.336
CD4 T cells, (%)	0.104	0.205	0.465
Treg memory, (%)	0.073	0.229	0.486
CD4 Tem Late, (%)	-0.046	0.232	0.465
CD4 TemRA Early, (%)	0.100	0.258	0.487
T cells, (%)	0.157	0.293	0.524
CD8 T cells, (%)	-0.095	0.294	0.499
Memory B cells, (%)	-0.082	0.334	0.540
T Follicular helper, (%)	0.099	0.350	0.540
CD16 ⁺ monocytes, (%)	-0.021	0.458	0.677
Treg naive, (%)	-0.053	0.460	0.651
CD8 Tem Late, (%)	0.093	0.480	0.653
CD16 ⁻ monocytes, (%)	0.070	0.547	0.716
B cells, (%)	-0.061	0.572	0.720
CD8 Naive, (%)	-0.100	0.662	0.804
Plasmablasts, (%)	-0.037	0.694	0.814
Regulatory T cells, (%)	-0.041	0.726	0.823
CD8 TemRA Early, (%)	-0.037	0.728	0.798
NK CD56 ^{DIM} , (%)	0.016	0.825	0.877
NK CD56 ^{BRIGHT} , (%)	-0.024	0.825	0.850
CD4 TemRA, (%)	0.004	0.893	0.893

Note:

The (Spearman) associations are ordered by p value, with the lowest p values shown at the top. Associations that were selected with a FDR lower than 15% are shown in bold

* False Discovery Rate (estimated)

Figures




Figure 1

Subpopulations of (a) T cells, (b) B cells, (c) NK cells, (d) Monocytes, and (e) Neutrophils, of which absolute cell numbers were determined. CM: central memory (CD4 or CD8 positive) T cells. Tem: effector memory (CD4 or CD8 positive) T cells. TemRA: effector memory T cells re-expressing CD45RA. See Table S1 for definition of all phenotypes. ¹Additionally analyzed on expression of CD38 and HLA-DR. ²Additionally analyzed on expression of CD16.




Figure 2

The numbers of cells per leukocyte subpopulations in men (n=145) and women (n=144) above 60 years of age. The boxplots show median values with interquartile range. CM: central memory (CD4 or CD8 positive) T cells. Tem: effector memory (CD4 or CD8 positive) T cells. TemRA: effector memory T cells re-expressing CD45RA. *: Outcomes of tests of the association between leukocyte numbers and sex

(adjusted for age and CMV serostatus) which passed the Benjamini-Hochberg method at a false discovery rate of 15%.




Figure 3

The numbers of CD4 and CD8 Tem and TemRA cells in men (n=145) and women (n=144) above 60 years of age. The boxplots show median values with interquartile range. CM: central memory (CD4 or CD8 positive) T cells. Tem: effector memory (CD4 or CD8 positive) T cells. TemRA: effector memory T cells re-expressing CD45RA. *: Outcomes of tests of the association between leukocyte numbers and sex (adjusted for age and CMV serostatus) which passed the Benjamini-Hochberg method at a false discovery rate of 15%.




Figure 4

Variable importance plot showing the leukocyte subpopulations and other variables that are most helpful in predicting frailty in men (n=140) and women (n=137). Participants with missing frailty index score data (n=12) were excluded from analysis. The bold lines and dots represent the most important variables that show an increase in mean squared error (MSE) of >50%. See text for the meaning of variable importance.




Figure 5

Partial dependence plots illustrating the role of the most important leukocyte phenotypes in predicting frailty in a random forest predictor for men ($n=140$) and women ($n=137$). Participants with missing frailty index score data ($n=12$) were excluded from analysis. The short vertical segments on the horizontal axis represent the deciles of the cell numbers in the data. Range of the figures is restricted to the part containing most of the data.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [FigureS3gatingothercellsV2.pdf](#)
- [FigureS1gatinggeneralV3.pdf](#)
- [FigureS2gatingTcellsV2.pdf](#)